Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

INDUSTRY 3 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 90 Prostatic Neoplasms 55 Lymphoma 34 Leukemia 32 Carcinoma, Non-Small-Cell Lung 31 Multiple Myeloma 30 Head and Neck Neoplasms 30 Colorectal Neoplasms 29 Squamous Cell Carcinoma of Head and Neck 28 Lung Neoplasms 27 Precursor Cell Lymphoblastic Leukemia-Lymphoma 25 Colonic Neoplasms 24 Leukemia, Myeloid, Acute 22 Rectal Neoplasms 21 Neoplasm Metastasis 20 Sarcoma 19 Ovarian Neoplasms 19 Central Nervous System Neoplasms 18 Uterine Cervical Neoplasms 17 Hodgkin Disease 17 Burkitt Lymphoma 15 Brain Neoplasms 15 Carcinoma, Ovarian Epithelial 14 Pain 12 Lymphoma, Follicular 12 Urinary Bladder Neoplasms 11 Lymphoma, Large B-Cell, Diffuse 11 Fallopian Tube Neoplasms 11 Endometrial Neoplasms 11 Astrocytoma 11

Interventions

telotristat ethyl 1 lanreotide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × NETWORK × Serotonin Syndrome × Clear all

NCT04065165 2020-02-05

TELEFIRST

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn

Carcinoid Heart Disease, Serotonin Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡